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Abstract
Background: Treatment options for metastatic renal cell carcinoma (RCC) are limited due to
resistance to chemo- and radiotherapy. The development of small-molecule multikinase inhibitors
has now opened novel treatment options. We evaluated the influence of the receptor tyrosine
kinase inhibitor AEE788, applied alone or combined with the mammalian target of rapamycin
(mTOR) inhibitor RAD001, on RCC cell adhesion and proliferation in vitro.
Methods: RCC cell lines Caki-1, KTC-26 or A498 were treated with various concentrations of
RAD001 or AEE788 and tumor cell proliferation, tumor cell adhesion to vascular endothelial cells
or to immobilized extracellular matrix proteins (laminin, collagen, fibronectin) evaluated. The anti-
tumoral potential of RAD001 combined with AEE788 was also investigated. Both, asynchronous
and synchronized cell cultures were used to subsequently analyze drug induced cell cycle
manipulation. Analysis of cell cycle regulating proteins was done by western blotting.
Results: RAD001 or AEE788 reduced adhesion of RCC cell lines to vascular endothelium and
diminished RCC cell binding to immobilized laminin or collagen. Both drugs blocked RCC cell
growth, impaired cell cycle progression and altered the expression level of the cell cycle regulating
proteins cdk2, cdk4, cyclin D1, cyclin E and p27. The combination of AEE788 and RAD001 resulted
in more pronounced RCC growth inhibition, greater rates of G0/G1 cells and lower rates of S-
phase cells than either agent alone. Cell cycle proteins were much more strongly altered when both
drugs were used in combination than with single drug application. The synergistic effects were
observed in an asynchronous cell culture model, but were more pronounced in synchronous RCC
cell cultures.
Conclusion: Potent anti-tumoral activitites of the multikinase inhibitors AEE788 or RAD001 have
been demonstrated. Most importantly, the simultaneous use of both AEE788 and RAD001 offered
a distinct combinatorial benefit and thus may provide a therapeutic advantage over either agent
employed as a monotherapy for RCC treatment.
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Background
Renal cell carcinoma (RCC) has an extremely poor prog-
nosis with a third of patients presenting with metastatic
disease at primary diagnosis and approximately 40%
experiencing tumor recurrence after surgical treatment for
localized disease. Treatment regimens for metastatic dis-
ease included surgical tumor size reduction, followed by
immunotherapy. However, the response rate in patients
with immunological approaches remains below 10 to
15% and life is prolonged only in highly selected patients
[1].
During recent years small-molecule multikinase inhibi-
tors have been developed which target ligands at the
molecular level and which may provide a disease-specific
therapy for patients with advanced forms of RCC. Indeed,
a profound improvement was seen in a trial comparing
sunitinib that inhibits the vascular endothelial growth fac-
tor (VEGF) receptor and related receptors with interferon-
alpha (IFNa) in previously untreated patients with RCC
[2].
However, although a higher objective response rate was
seen in the sunitinib arm, as was a longer progression-free
survival time, 13% of the patients died in the sunitinib
arm versus 17% in the IFNa arm which was not significant
in this analysis (it should be noted that crossover to the
sunitinib arm was allowed, which may mask any ultimate
survival benefit). Similarly, sorafenib, another VEGF
receptor tyrosine kinase inhibitor, given as second line
treatment in a placebo-controlled trial, caused a response
in 10% of patients but the difference in survival was not
statistically significant [3].
There is also biologic rationale for targeting the epidermal
growth factor (EGF) receptor for the treatment of RCC.
Still, clinical trials to date have yielded disappointing
results. Lapatinib prolonged overall survival and showed
a trend towards improved time to progression in a sub-
group of patients with tumors that overexpressed the EGF
receptor (compared to standard hormone therapy) [4].
Gefitinib (Iressa) did not induce objective responses in a
small cohort of relapsed RCC but disease control was
observed in 53.8% of patients [5].
Obviously, the present concept of targeted therapy pro-
vides delayed progression and extended survival, how-
ever, responses are mostly partial and of limited duration.
Since aberrant cancer-causing pathways address multiple
components, we assume that single drug treatment may
not be sufficient for long-term control of RCC, either due
to the development of resistance or due to the develop-
ment of compensatory feedback loops. In fact, it has
recently been observed that blockade of the EGF receptor
signaling was compensated by an enhanced VEGF synthe-
sis, providing an important survival advantage of VEGF
receptor expressing tumor cells [6,7].
The cross-communication between EGF and VEGF signal-
ing suggests that associated targeting of both receptor
types may be an adequate approach to block RCC growth
and progression. Surprisingly, combined anti-EGF and
anti-VEGF receptor agents seem not be sufficient to
achieve a distinct therapeutic benefit in cancer patients
[8]. Thus, additional intra-tumoral events correlated to
RCC progression should be considered when designing a
powerful treatment strategy.
Novel data have shown that RCC exhibits constitutive
activation of the phosphatidylinositol 3-kinase (PI3K) –
Akt – mammalian target of rapamycin (mTOR) pathway,
the downstream effector of VEGF and EGF receptor sign-
aling [9,10]. Most importantly, the PI3K-Akt-mTOR path-
way is an important mediator of resistance to
conventional chemotherapy and to targeted therapy
based on EGF or VEGF receptor tyrosine kinase inhibitors
[11].
We concluded from these reports that both horizontal
and vertical down-regulation of growth factor receptor
related signaling may be required to optimize the current
protocol of tumor targeting. Particularly, simultaneous
blocking of EGF and VEGF receptor activation combined
with Akt-mTOR inhibition may profoundly increase the
magnitude and duration of anti-tumor effects exerted by
single agent application. To proof this hypothesis, we
evaluated the influence of the orally available mTOR
inhibitor RAD001 (everolimus), applied alone or com-
bined with the dual EGF and VEGF receptor tyrosine
kinase inhibitor AEE788 [12], on RCC cell adhesion and
proliferation in vitro. Our results indicate that both
AEE788 and RAD001 exert potent anti-tumor activity.
However, combined use of both compounds seems to be
more effective than the single drug application and thus
may provide a therapeutic advantage over either agent as
monotherapy for RCC treatment.
Methods
Cell cultures
Kidney carcinoma Caki-1 and KTC-26 cells were pur-
chased from LGC Promochem (Wesel, Germany). A498
cells were derived from CLS (Heidelberg, Germany).
Tumor cells were grown and subcultured in RPMI 1640
medium (Seromed, Berlin, Germany) supplemented with
10% FCS, 100 IU/ml penicillin and 100 μg/ml streptomy-
cin at 37°C in a humidified, 5% CO2 incubator. Endothe-
lial cells (HUVEC) were isolated from human umbilical
veins and harvested by enzymatic treatment with chymo-
trypsin. HUVEC were grown in Medium 199 (Biozol,
Munich, Germany), 10% fetal calf serum (FCS; Gibco,BMC Cancer 2009, 9:161 http://www.biomedcentral.com/1471-2407/9/161
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Karlsruhe, Germany), 10% pooled human serum (Blood
Bank of The German Red Cross, Frankfurt am Main, Ger-
many), 20 μg/ml endothelial cell growth factor (Boe-
hringer, Mannheim, Germany), 0.1% heparin (Roche,
Basel, Switzerland), 100 ng/ml gentamycin (Gibco) and
20 mM HEPES-buffer (Seromed, Berlin, Germany). Cell
cultures were serially passaged. Subcultures from passages
2–4 were selected for experimental use.
Drugs
AEE788 and RAD001 (provided by Novartis Pharma AG,
Basel, Switzerland) were dissolved in DMSO as 10 mM
stocks and stored as aliquots at -20°C. RCC cells were
treated either with AEE788 or with RAD001 at concentra-
tions indicated in the results section. Combination treat-
ment with both compounds was based on 1 μM AEE788
and 1 nM RAD001. Controls remained untreated. In addi-
tional experiments, AEE788 was compared to tyrosine
kinase inhibitors which are currently in clinical use: gefit-
inib, erlotinib or sunitinib (LC Laboratories, Woburn,
MA, USA; 1 μM each). To exclude toxic effects of the com-
pounds, cell viability was determined by trypan blue
(Gibco/Invitrogen). For apoptosis detection the expres-
sion of Annexin V/propidium iodide (PI) was evaluated
using the Annexin V-FITC Apoptosis Detection kit (BD
Pharmingen, Heidelberg, Germany). Tumor cells were
washed twice with PBS, and were then incubated with 5 μl
of Annexin V-FITC and 5 μl of PI in the dark for 15 min at
RT. Cells were analyzed on a FACScalibur (BD Bio-
sciences, Heidelberg, Germany). The percentage of apop-
totic cells (early and late) in each quadrant was calculated
using CellQuest software (BD Biosciences).
Tumor cell adhesion
To analyze tumor cell adhesion, HUVEC were transferred
to 6-well multiplates (Falcon Primaria; BD Biosciences) in
complete HUVEC-medium. When confluency was
reached, Caki-1, KTC-26 or A498 cells were detached from
the culture flasks by accutase treatment (PAA Laborato-
ries, Cölbe, Germany) and 0.5 × 106 cells were then added
to the HUVEC monolayer for 60 min. Subsequently, non-
adherent tumor cells were washed off using warmed
(37°C) Medium 199. The remaining cells were fixed with
1% glutaraldehyde. Adherent tumor cells were counted in
five different fields of a defined size (5 × 0.25 mm2) using
a phase contrast microscope and the mean cellular adhe-
sion rate was calculated.
Attachment to extracellular matrix components
6-well plates were coated with collagen G (extracted from
calfskin, consisting of 90% collagen type I and 10% colla-
gen type III; Seromed; diluted to 100 μg/ml in PBS), lam-
inin (derived from the Engelbreth-Holm-Swarm mouse
tumor; BD Biosciences; diluted to 50 μg/ml in PBS), or
fibronectin (derived from human plasma; BD Biosciences;
diluted to 50 μg/ml in PBS) overnight. Unspecific cell
binding was evaluated by culture plates treated with Poly-
D-Lysin (Nunc, Wiesbaden, Germany). Plastic dishes
served as the background control. Plates were washed
with 1% BSA (bovine serum albumin) in PBS to block
nonspecific cell adhesion. Thereafter, 0.5 × 106 tumor cells
were added to each well for 60 min. Subsequently, non-
adherent tumor cells were washed off, the remaining
adherent cells were fixed with 1% glutaraldehyde and
counted microscopically. The mean cellular adhesion
rate, defined by adherent cellscoatedwell – adherent cellsback-
ground, was calculated from five different observation
fields.
Measurement of tumor cell growth
Cell proliferation was assessed using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
dye reduction assay (Roche Diagnostics, Penzberg, Ger-
many). Treated versus non-treated Caki-1, KTC-26 or
A498 cells (100 μl, 1 × 104 cells/ml) were seeded onto 96-
well tissue culture plates. After 24, 48 and 72 h, MTT (0.5
mg/ml) was added for an additional 4 h. Thereafter, cells
were lysed in a buffer containing 10% SDS in 0.01 M HCl.
The plates were allowed to stand overnight at 37°C, 5%
CO2. Absorbance at 570 nm was determined for each well
using a microplate ELISA reader. Each experiment was
done in triplicate. After subtracting background absorb-
ance, results were expressed as mean cell number.
Cell cycle analysis
Caki-1 or A498 cells were grown to 70% confluency and
then treated with AEE788 or with RAD001 or with both
AEE788 + RAD001 (controls remained untreated). Cell
cycle analyses were carried out after 24 h using both asyn-
chronous and synchronous cell populations. Caki-1 or
A498 cells were synchronized at the G1-S boundary with
aphidicolin (1 μg/ml) 24 h before starting cell cycle anal-
ysis and subsequently resuspended in fresh (aphidicolin
free) medium for 2 h. Asynchronous or synchronous
tumor cell populations were stained with propidium
iodide using a Cycle TEST PLUS DNA Reagent Kit (Becton
Dickinson) and then subjected to flow cytometry with a
FACScan flow cytometer (Becton Dickinson). 10,000
events were collected from each sample. Data acquisition
was carried out using Cell-Quest software and cell cycle
distribution calculated using the ModFit software (Becton
Dickinson). The number of gated cells in G1, G2/M or S-
phase was presented as %.
Western Blot Analysis
Cell cycle regulating proteins were explored in asynchro-
nous and synchronous tumor cell populations. Tumor
cell lysates were applied to a 7% polyacrylamide gel and
electrophoresed for 90 min at 100 V. The protein was then
transferred to nitrocellulose membranes. After blockingBMC Cancer 2009, 9:161 http://www.biomedcentral.com/1471-2407/9/161
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with non-fat dry milk for 1 h, the membranes were incu-
bated overnight with the following monoclonal antibod-
ies: Cdk2 (IgG2a, clone 55, dilution 1:2.500), cdk4 (IgG1,
clone 97, dilution 1:250), cyclin D1 (IgG1, clone G124–
326, dilution 1:250), cyclin E (IgG1, clone HE12, dilution
1:200), p27 (IgG1, clone 57, dilution 1:500; all: BD Bio-
sciences, Heidelberg, Germany). HRP-conjugated goat-
anti-mouse IgG (Upstate Biotechnology, Lake Placid, NY,
USA; dilution 1:5.000) served as the secondary antibody.
The membranes were briefly incubated with ECL detec-
tion reagent (ECL™, Amersham/GE Healthcare, München,
Germany) to visualize the proteins and exposed to an x-
ray-film (Hyperfilm™ EC™, Amersham/GE Healthcare). β-
actin (1:1.000; Sigma, Taufenkirchen, Germany) served as
the internal control.
For control purposes, EGF receptor and mTOR signaling
were evaluated. A498 or Caki-1 cells were treated with
AEE788 or RAD001 or with the AEE788-RAD001 combi-
nation for 24 h. Cells were then kept for 2 h in serum-free
cell culture medium and subsequently stimulated for 30
min with EGF (100 ng/ml). The following monoclonal
antibodies were used: Akt (IgG1, clone 55, dilution
1:500), phospho Akt (IgG1, clone 104A282, dilution
1:500), ERK1 (IgG1, clone MK12, dilution 1:5000), ERK2
(IgG2b, clone 33, dilution 1:5000), phospho ERK1/2
(IgG1, clone 20A, dilution 1:1000), EGFr (IgG1, clone 13/
EGFR, dilution 1:500), phospho EGFr (IgG1, clone 74,
dilution 1:1000; all: BD Biosciences), p70S6K (IgG, clone
49D7, dilution 1:1000), phospho p70S6K (IgG, clone
108D2, dilution 1:1000; all: New England Biolabs, Frank-
furt, Germany).
Statistics
All experiments were performed 3–6 times. Statistical sig-
nificance was investigated by the Wilcoxon-Mann-Whit-
ney-U-test. Differences were considered statistically
significant at a p value less than 0.05.
Results
Dose-response analysis
AEE788 or RAD001 were added to RCC cell cultures and
proliferation quantified 24, 48 and 72 h after plating. To
clearly interpret and compare cellular growth characteris-
tics, 24 h counts were all set at 100%. Incubation with
AEE788 dose-dependently and significantly down-regu-
lated RCC cell proliferation (fig. 1a). 5 μM AEE788 com-
pletely stopped RCC cell growth. Based on these data, the
sub-optimal concentration of 1 μM AEE788 was chosen
for subsequent combination experiments. Fig. 1b demon-
strates the influence of RAD001 on RCC growth character-
istics. Maximum effects were induced when cells were
exposed to 5 nM (A498, Caki-1) or 10 nM RAD001 (KTC-
26). The trypan blue assay revealed no signs of drug toxic-
ity. For ongoing studies, the sub-optimal concentration of
1 nM RAD001 was used.
RCC adhesion to HUVEC or immobilized extracellular 
matrix proteins
Single drug application of either 1 μM AEE788 or 1 nM
RAD001 induced a slight but significant down-regulation
of RCC cell attachment to HUVEC, compared to the
untreated controls (fig. 2). Surprisingly, simultaneous
exposure of RCC cells to both AEE788 and RAD001 did
not always led to a further decrease of the tumor cell
attachment rate, compared to the single drug regimen. A
stronger response was only seen with respect to KTC-26
but not with respect to the A498 and Caki-1 cells (fig. 2).
Effects of AEE788 and/or RAD001 on RCC cell binding to
extracellular matrix strongly depended on the matrix pro-
tein used. RCC cell attachment to collagen was signifi-
cantly diminished by AEE788 or RAD001, the AEE-RAD
combination being more effective than the single drug
application (fig. 3). Similarly, interaction of RCC cells
with immobilized laminin was blocked distinctly by
AEE788 or RAD001, and the combination therapy was
superior than the single drug treatment (fig. 3). In con-
trast, binding of Caki-1 to fibronectin was not influenced
neither by the single drug nor by the AEE-RAD combina-
tion. KTC-26 binding to fibronectin was blocked by
AEE788 exclusively, whereas A498 binding was signifi-
cantly reduced only when both compounds were used in
combination (fig. 3). No drug effects were seen on RCC
cell lines grown on Poly-D-Lysin coated dishes.
AEE788 and RAD001 block RCC cell growth
The proliferative response of RCC to AEE788 and/or
RAD001 treatment was analyzed next. Growth of A498,
Caki-1 and KTC-26 cells was inhibited significantly by
each drug alone. AEE788 and RAD001 induced similar
effects on A498 and KTC-26 cells, whereas AEE788 was
superior to RAD001 in the Caki-1 cells (fig. 4). The com-
bination of both drugs further decreased the proliferation
rate of all RCC cell lines, compared to the single drug
application. AEE788 was additionally compared to kinase
inhibitors currently in clinical use. The EGF receptor tyro-
sine kinase inhibitors erlotinib and gefitinib, each applied
at 1 μM, significantly reduced RCC cell proliferation (erlo-
tinib > gefitinib; fig. 4+5). However, both agents were not
as potent as was 1 μM AEE788. Furthermore, erlotinib-
RAD001 and gefitinib-RAD001 combination reduced cell
growth to a lesser extent than the AEE788-RAD001 com-
bination. The same was true when the VEGF receptor
inhibitor sunitinib was applied (fig. 5). Even, cell growth
of A498 was not diminished at all by sunitinib. In all
experiments, the Annexin V-FITC assay did not reveal any
signs of apoptosis. Therefore, cell growth reduction due toBMC Cancer 2009, 9:161 http://www.biomedcentral.com/1471-2407/9/161
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apoptotic events could be excluded. Ongoing studies con-
centrated on the influence of AEE788 and RAD001 on cell
cycle progression and cell cycle regulating proteins.
AEE788 and RAD001 impair cell cycle progression
Cell cycle analysis was carried out on A498 and Caki-1
cells. Based on asynchronous A498 cell populations,
AEE788 and RAD001 significantly decreased the amount
of S-phase and enriched the amount of G0/G1 cells. Both
compounds evoked similar effects on A498 cells, inde-
pendent on the concentration used (1 μM versus 5 μM;
fig. 6a, left). Cell cycle progression of asynchronous Caki-
1 cells were also affected by AEE788 and RAD001, how-
ever AEE788 was more potent than RAD001 in this matter
(fig. 6b, left). The maximum cell cycle blockade was
achieved when 1 μM AEE788 and 1 nM RAD001 were
added to RCC cells in combination.
Subsequently, A498 or Caki-1 cells were released from an
aphidicolin block to enrich the mitotic population (fig. 6
a+b, right). In doing so, 1 μM AEE788 or 1 nM RAD001
distinctly delayed cell cycle entry, AEE788 being more
Effects of AEE788 (1a) or RAD001 (1b) on kidney cancer proliferation in vitro Figure 1
Effects of AEE788 (1a) or RAD001 (1b) on kidney cancer proliferation in vitro. A498, Caki-1 or KTC-26 cells were 
treated with various concentrations of AEE788 or RAD001, or remained untreated (control). Cell proliferation was then 
assessed using the MTT dye reduction assay. Cell numbers at day 2 and 3 (48 h and 72 h) were compared to the number on 
day 1 (24 h, as 100%). One representative of 6 experiments is shown. * indicates significant difference to controls (p < 0.05). 
SDintraassay < 15%.
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effective than RAD001. Combined application of both
agents in the 1 μM/1 nM formulation induced much
stronger alterations on the cell cycle than the 1 μM
AEE788 or 1 nM RAD001 single drug application. Effects
induced by the 1 μM/1 nM drug combination were then
similar to those seen under 5 μM AEE788 and even more
intense than seen under 5 nM RAD001 single drug appli-
cation.
AEE788 and RAD001 alter expression level of cell cycle 
proteins
Alteration of cell cycle regulating proteins strongly
depended on the drug exposure time, the drug dosage and
the RCC cell line used. With respect to asynchronous
A498 cells, cdk2 was lowered after 6 h by 1 or 5 μM
AEE788 or by 5 nM RAD001 but enhanced by 1 nM
RAD001, compared to the controls (fig. 7). 24 h analysis
revealed cdk2 reduction by both AEE788 and RAD001.
Cdk4 was found to be up-regulated, notably by 1 μM
AEE788 or 1 nM RAD001 after a 6 h exposure. Cyclin D1
was mainly diminished by AEE788 after 6 and 24 h,
whereas cyclin E was enhanced after the same time period
mainly by RAD001. p27 was drastically elevated after 6
and 24 h by both compounds, compared to the non-
treated controls.
AEE788 and RAD001 also manipulated protein expres-
sion in asynchronous Caki-1 and KTC-26 cell cultures.
Alterations in Caki-1 cells predominantly corresponded
to the kind of manipulation in A498 cells (fig. 7). How-
Adhesion of RCC cells to HUVEC Figure 2
Adhesion of RCC cells to HUVEC. A498, Caki-1 or KTC-26 cells were treated with 1 μM AEE788 or 1 nM RAD001, 
applied alone or in combination. After a 1 h pre-incubation, tumor cells were added at a density of 0.5 × 106 cells/well to 
HUVEC monolayers for 60 min. Non-adherent tumor cells were washed off in each sample, the remaining cells were fixed and 
counted in five different fields (5 × 0.25 mm2) using a phase contrast microscope. Mean values were calculated from five 
counts. Mean adhesion capacity is depicted as adherent cells/mm2. One representative of six experiments is shown. * indicates 
significant difference to controls (p < 0.05).
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ever, major differences were seen in KTC-26 cells, since
cdk4 and cyclin D1 became all elevated by AEE788 or
RAD001, whereas cyclin E was reduced by AEE788 after a
6 and 24 h drug exposure (fig. 7).
The AEE788-RAD001 combination experiments yielded
ambiguous results. Additive effects became obvious in
A498 cells with respect to cdk2 expression (24 h), in Caki-
1 cells with respect to p27 expression (24 h). This was not
true in the KTC-26 cell model. However, cyclin E (6 h, 24
h) was diminished to a greater extent in these cells by the
AEE788-RAD001 combination compared to the single
drug application.
When drug treatment and protein analysis was carried out
in the synchronous cell culture model, a clearer picture
was obtained (fig. 8, 9, 10). As a general rule, cdk2, cdk4,
cyclin D1 and cyclin E were all found to be down-regu-
lated by AEE788 or RAD001. Still, few exceptions
remained demonstrating no changes or even elevated pro-
tein expression, compared to the controls. Alterations of
the p27 expression level took place 6 and 24 h after the
experimental start, becoming enhanced in A498 and Caki-
1 cells by AEE788. The same effect was evoked by RAD001
in Caki-1. Interestingly, AEE788 reduced p27 expression
in KTC-26 cells, whereas RAD001 enhanced it (6 h analy-
sis).
Adhesion of RCC cells to extracellular matrix proteins Figure 3
Adhesion of RCC cells to extracellular matrix proteins. A498, Caki-1 or KTC-26 cells were treated with 1 μM AEE788 
or 1 nM RAD001, applied alone or in combination. Non-treated cells served as the controls. Cells were then added to immo-
bilized collagen, laminin, or fibronectin at a density of 0.5 × 106 cells/well for 60 min. Plastic dishes were used to evaluate 
unspecific binding (background control). Non-adherent tumor cells were washed off in each sample, the remaining cells were 
fixed and counted in five different fields (5 × 0.25 mm2) using a phase contrast microscope. Mean values were calculated from 
the five counts. Specific adhesion capacity (background adhesion on plastic surface was subtracted from adhesion to matrix 
proteins) is depicted as adherent cells/mm2. One representative of six experiments is shown. * indicates significant difference 
to controls (p < 0.05).
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AEE788-RAD001 combination treatment strongly aug-
mented the effects of the single drug treatment in all cell
lines investigated. In particular, cdk2, cdk4, cyclin D1 and
cyclin E were drastically reduced or even lost at specific
time points in A498 and KTC-26 cells when both agents
were used together.
Analysis of mTOR and EGF receptor signaling
Finally, we evaluated if AEE788 and/or RAD001 effects are
linked to the inhibition of their primary targets. Total EGF
receptor, ERK1/2, Akt and p70S6K were not changed by
both agents (fig. 11). However, amount of activated EGF
receptor was diminished by AEE788 in Caki-1 and A498
cells. Activated EGF receptor was also found to be reduced
in presence of the AEE788-RAD001 drug combination.
Phosphorylated ERK1/2 became lost by AEE788 or the
AEE788-RAD001 drug combination in A498 cells. This
phenomenon was not seen in Caki-1 cells. Interestingly,
activation of Akt was only slightly down-regulated by
RAD001 in A498 cells, and the response of Caki-1 cells to
RAD001 was only marginal in this matter. However,
RAD001 strongly inhibited p70S6K activation in both
Caki-1 and A498 cells. Very strong deactivation of p70S6K
was achieved by the AEE788-RAD001 drug combination
in A498 cells.
Discussion
AEE788 is a 7H-pyrrolo [2,3-d]pyrimidine-class receptor
tyrosine kinase inhibitor that potently inhibits the EGFR
associated kinase activity (IC50: 2 nM) with additional
Effects of RAD001, AEE788 or erlotinib versus drug combination on kidney cancer proliferation in vitro Figure 4
Effects of RAD001, AEE788 or erlotinib versus drug combination on kidney cancer proliferation in vitro. A498, 
Caki-1 or KTC-26 cells were treated with 1 nM RAD001, 1 μM AEE788 or 1 μM erlotinib, applied alone or in combination. 
Controls remained untreated. Cells were then counted after a further 24, 48 and 72 h using the MTT dye reduction assay. One 
representative of 6 experiments is shown. * indicates significant difference to controls (p < 0.05).
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inhibition of VEGFR-1 (Flt-1; IC50: 59 nM) and VEGFR-2
(kinase domain region/Flk-1; IC50: 77 nM) at higher con-
centrations [12]. Anti-proliferative effects of this com-
pound have already been demonstrated on prostate [13],
colon [14], pancreatic [15], lung, ovarian [16], and gliob-
lastoma cell lines [17]. Evidence is presented here show-
ing that AEE788 in the μM range interferes with the RCC-
endothelium and RCC-matrix communication and alters
RCC cell growth dynamics.
A significant decrease of S-phase and concomitant
increase of G0/G1 phase cells was seen in the presence of
AEE788 accompanied by distinct modifications of cell
cycle regulating proteins. The data were more concise in
the synchronous than in the asynchronous cell culture
model, which is not surprising because specific effects of
AEE788 on mitotic events may become more obvious in a
homogeneous cell population. Indeed, Peng and cowork-
ers reported that the activity of a particular drug limited to
certain cell cycle phases may be diluted under asynchro-
nous conditions [18]. Based on the synchronous cell cul-
ture model, cdk2, cdk4, cyclin D1 and cyclin E were all
found to be reduced, whereas p27 was up-regulated by
AEE788 in the RCC cell lines.
These findings are important since disturbances of cell
cycle control in the tumorigenesis of RCC have recently
been shown to be paralleled by elevation of cyclin D1 and
Effects of RAD001, gefitinib or sunitinib versus drug combination on kidney cancer proliferation in vitro Figure 5
Effects of RAD001, gefitinib or sunitinib versus drug combination on kidney cancer proliferation in vitro. A498, 
Caki-1 or KTC-26 cells were treated with 1 nM RAD001, 1 μM gefitinib or 1 μM sunitinib, applied alone or in combination. 
Controls remained untreated. Cells were then counted after a further 24, 48 and 72 h using the MTT dye reduction assay. One 
representative of 6 experiments is shown. * indicates significant difference to controls (p < 0.05).
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cdk4, accompanied by the attenuation of p27 expression
[19]. Inline with the in vitro data, analysis of tumor speci-
men taken from RCC patients revealed a correlation
between cyclin D1 and cyclin E protein level and the
tumor proliferation index [20]. Vice versa, an inverse cor-
relation was seen between p27 expression and tumor size,
and RCC patients with p27 low tumors had poorer sur-
vival than patients with p27 high tumors [21,22].
Obviously, cyclin D1, cyclin E, cdk4 and p27 represent
pivotal elements in RCC cells and targeting these proteins
may become an intriguing option to stop RCC progres-
sion. In fact, incubation of RCC cells with thiazolidinedi-
one decreased the protein levels of cyclin D1 and cdk4,
and increased the levels of p27 which altogether led to
G0/G1 arrest and massive tumor cell apoptosis [23]. A
similar phenomenon has been observed by others treating
Cell cycle analysis of A498 (6a) and Caki-1 cells (6b) Figure 6
Cell cycle analysis of A498 (6a) and Caki-1 cells (6b). Asynchronous (left) and synchronous (right) cell cultures were 
used. Cells were treated either with 1 μM or 5 μM AEE788 or with 1 nM or 5 nM RAD001, or with a 1 μM AEE788-1nM 
RAD001 combination. Controls remained untreated. The cell population at each specific checkpoint is expressed as percent-
age of the total cells analyzed. One representative experiment of three is shown.
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RCC cells with the short chain fatty acid sodium butyrate
or phenylacetate [24,25].
The data presented here point to a powerful anti-tumoral
activity of AEE788. Nevertheless, AEE788 did not reduce
cyclin D1, cyclin E, cdk2 and cdk4 at all time points ana-
lyzed. Cdk1 became even (slightly) enhanced in synchro-
nized KTC-26 and A498 cells after 1 h (1 μM application).
Therefore, it may be assumed that AEE788 does not com-
pletely suppress cell mitosis but rather slows down the
mitotic cycle. In line with this speculation, the prolifera-
tive activity of RCC cells presented in figure 4 was drasti-
cally down-regulated, though not totally blocked by
AEE788.
RAD001, the 40-O-(2-hydroxyethyl) derivative of
rapamycin [26], blocks proliferation of several tumor cell
lines in vitro. No detailed analysis has been carried out on
RCC cell lines. However, clinical trials confirm the rele-
vance of targeting the mTOR pathway in RCC [27-29].
RAD001 has recently been shown to exhibit a partial
response (23%) and stable disease (38%) in a phase II
trial of patients with RCC. Progression-free survival was
11.2 months [30]. Another phase II trial evaluating
RAD001 was presented at ASCO 2008 and shows encour-
aging anti-tumor activity in RCC patients which have had
prior exposure to sorafenib or sunitinib [31]. Finally,
Western blot analysis of cell cycle proteins, listed in methods Figure 7
Western blot analysis of cell cycle proteins, listed in 
methods. Asynchronous A498, Caki-1 or KTC-26 cells 
were treated either with 1 μM or 5 μM AEE788 or with 1 
nM or 5 nM RAD001, or with a 1 μM AEE788-1nM RAD001 
combination. Controls remained untreated. Drugs were 
applied for 6 or 24 h. Cell lysates were then subjected to 
SDS-PAGE and blotted on the membrane incubated with the 
respective monoclonal antibodies. Beta-actin served as the 
internal control. The figure shows one representative from 
three separate experiments.
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Western blot analysis of cell cycle proteins, listed in methods. Synchronized A498 (Fig. 8), Caki-1 (Fig. 9) or KTC-26 
cells (Fig. 10) were treated either with 1 μM or 5 μM AEE788 or with 1 nM or 5 nM RAD001, or with a 1 μM AEE788-1nM 
RAD001 combination. Controls remained untreated. Drugs were applied for 1, 3, 6, or 24 h. Cell lysates were then subjected 
to SDS-PAGE and blotted on the membrane incubated with the respective monoclonal antibodies. Beta-actin served as the 
internal control. The figures show one representative from three separate experiments.
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treatment with RAD001 prolonged progression-free sur-
vival relative to placebo in patients with metastatic RCC in
a phase III study [32].
We present evidence that RAD001 significantly influences
RCC adhesion and growth behaviour. RAD001 had a dis-
tinct impact on the suppression of cellular S-phase frac-
tion and modification of cell cycle protein expression.
Remarkably, RAD001's effects on cell cycle proteins did
not always parallel the characteristics of AEE788. Notably,
cyclin D1 were found to be reduced by AEE788 in syn-
chronized Caki-1 cells but remained unchanged in the
presence of RAD001 at a particular time point. It is not
clear if cyclin D1 is incompletely targeted by RAD001
Western blot analysis of cell cycle proteins, listed in methods Figure 9
Western blot analysis of cell cycle proteins, listed in methods. Synchronized A498 (Fig. 8), Caki-1 (Fig. 9) or KTC-26 
cells (Fig. 10) were treated either with 1 μM or 5 μM AEE788 or with 1 nM or 5 nM RAD001, or with a 1 μM AEE788-1nM 
RAD001 combination. Controls remained untreated. Drugs were applied for 1, 3, 6, or 24 h. Cell lysates were then subjected 
to SDS-PAGE and blotted on the membrane incubated with the respective monoclonal antibodies. Beta-actin served as the 
internal control. The figures show one representative from three separate experiments.
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Western blot analysis of cell cycle proteins, listed in methods Figure 10
Western blot analysis of cell cycle proteins, listed in methods. Synchronized A498 (Fig. 8), Caki-1 (Fig. 9) or KTC-26 
cells (Fig. 10) were treated either with 1 μM or 5 μM AEE788 or with 1 nM or 5 nM RAD001, or with a 1 μM AEE788-1nM 
RAD001 combination. Controls remained untreated. Drugs were applied for 1, 3, 6, or 24 h. Cell lysates were then subjected 
to SDS-PAGE and blotted on the membrane incubated with the respective monoclonal antibodies. Beta-actin served as the 
internal control. The figures show one representative from three separate experiments.
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(particularly in Caki-1 cells) or if RAD001 acts in a differ-
ent manner than AEE788. Studies on malignant glioblas-
toma cells revealed both compounds to affect cellular
proliferation in different ways [33]. Therefore, non-over-
lapping mechanisms should be considered when inter-
preting our data. This is an important issue, as some
targeted therapies require the cell to enter specific cell
cycle points to induce therapeutic effects.
As the most important message, simultaneous use of both
AEE788 and RAD001 offered a distinct combinatorial
benefit and thus may provide a therapeutic advantage
over either agent as monotherapy for RCC treatment. This
is highly relevant, since single agents rarely induced com-
plete responses in clinical trials, presumably due to com-
pensatory cross-talk among receptors within a signaling
network as well as with heterologous receptor systems in
RCC cells. Combinations of targeted agents could
improve limited therapeutic efficacy and overcome resist-
ance that might develop under single-agent therapy. At
the present, two different concepts of combination tar-
geted therapy for RCC are discussed. "Horizontal block-
ade" is aimed to concurrently target numerous molecules
involved in RCC proliferation and dissemination (e. g.
simultaneous targeting of the EGF and VEGF receptor).
The other popular concept of "vertical blockade" is aimed
to target the same pathway at two or more different levels.
Concerning the latter, synergistic effects were seen in sev-
eral tumor cell lines when both mTOR and EGF receptor
inhibitors were administrated in combination [34-36].
Recent data suggest that combining mTOR with VEGF
receptor inhibitors may have clinical potential to enhance
survival of cancer patients [37,38].
The present study was designed to interfere with the
tumor cell signaling network horizontally and vertically
by targeting the VEGF receptor and EGF receptor as well as
the mTOR-Akt axis. The combinatorial impact of AEE788
and RAD001 was mainly seen in the suppression of RCC
proliferation. Results of the adhesion experiments are not
clear. Additive effects became evident with respect to KTC-
26 adhesion but not with respect to A498 and Caki-1
adhesion to HUVEC. AEE788-RAD001 combination
treatment also blocked RCC cell binding to laminin and
collagen to a higher extent than the monotherapy did.
However, this was not true in the fibronectin assay. Based
on our in vitro model, we postulate that synergism may
not be evoked against all the events in the evolution of
neoplastic disease and metastatic tumor dissemination.
Presumably, combinatorial application of AEE788 and
RAD001 may be favourable in blocking tumor growth,
whereas therapeutic modulation of tumor transmigration
may be limited to specific phases of the tumor cell inva-
sion cascade. Nevertheless, no data are available dealing
with this issue and, therefore, this is still speculative. Fur-
ther experiments are necessary to demonstrate how the
drugs modify RCC adhesion and migration behaviour,
and to characterize the relevant target proteins.
Conclusion
Our results indicate that the receptor tyrosine kinase
inhibitor AEE788 and the mTOR inhibitor RAD001 both
act on RCC cell adhesion and cell growth. Combined use
of both compounds seems to be more effective than single
drug application. This view is supported by findings in
glioblastoma cell lines, where the combination of AEE788
and RAD001 resulted in increased rates of cell cycle arrest
and apoptosis and reduced proliferation more than either
Western blot analysis of cell signaling proteins, listed in  methods Figure 11
Western blot analysis of cell signaling proteins, listed 
in methods. A498 or Caki-1 cells were treated either with 
1 μM AEE788 or with 1 nM RAD001, or with a 1 μM 
AEE788-1nM RAD001 combination. Controls remained 
untreated. Drugs were applied for 24 h. Cells were then kept 
for 2 h in serum-free cell culture medium and subsequently 
stimulated for 30 min with EGF (100 ng/ml). Cell lysates 
were subjected to SDS-PAGE and blotted on the membrane 
incubated with the respective monoclonal antibodies. Beta-
actin served as the internal control. The figure shows one 
representative from three separate experiments.
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agent alone [33]. Therefore, simultaneous use of both
AEE788 and RAD001 may offer a distinct combinatorial
benefit and thus may provide a therapeutic advantage
over either agent as monotherapy for RCC treatment. Ani-
mal experiments are necessary to deepen the in vitro find-
ings. Since VEGF receptors are strongly involved in
angiogenic events, the anti-angiogenic potential of both
drugs should also be evaluated in the in vivo model.
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